Neoadjuvant HER2+ Articles

Study Finds No Cardiac Toxicity Increase With Trastuzumab in HER2+ Breast Cancer Patients
Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
Novel Treatments Emerging in HER2+ Breast Cancer Pipeline
Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.
Pertuzumab and Other Agents Continue Progress in HER2+ Breast Cancer
Adam M. Brufsky, MD, PhD, discusses the developing role of pertuzumab in HER2-positive breast cancer, as well as the impact of other agents in the field.
Dual HER2 Blockade Superior for PFS in HER2+/HR+ Metastatic Breast Cancer
The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.
Long-Term Data Published for Neratinib in HER2+ Breast Cancer
Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.
Hamilton Highlights Treatment Landscape of HER2+ Breast Cancer
Erika P. Hamilton, MD, discusses recent FDA approvals in the treatment paradigm of HER2-positive breast cancer.
FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer
The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.
 
CHMP Issues Positive Opinion on Herzuma for HER2+ Breast, Gastric Cancers
The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
Precision Medicine a Necessary Component in HER2+ Breast Cancer Care
Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.
Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers
Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.
Publication Bottom Border
Border Publication
x